DrugPatentWatch Database Preview

LEXAPRO Drug Profile

see a sample report or, see our see our flat-rate plans

When do Lexapro patents expire, and when can generic versions of Lexapro launch?

Lexapro is a drug marketed by Allergan Sales Llc and is included in two NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has fifty-six patent family members in thirty-eight countries.

The generic ingredient in LEXAPRO is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.

Summary for LEXAPRO

International Patents:	56
US Patents:	2
Applicants:	1
NDAs:	2
Suppliers / Packagers:	13
Bulk Api Vendors:	99
Clinical Trials:	75
Patent Applications:	445
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEXAPRO
DailyMed Link:	LEXAPRO at DailyMed

Drug patent expirations by year for LEXAPRO

Pharmacology for LEXAPRO

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

Synonyms for LEXAPRO

(+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
(+)-(S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalate
(+)-(S)-Citalopram
(+)-(S)-Citalopram oxalate
(+)-Citalopram
(1r)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-3h-isobenzofuran-5-carbonitrile
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Ethanedioate
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; oxalic acid
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;oxalic acid
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile; oxalic acid
(S)-(+)-1-[3-(dimethylamino) propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
(S)-(+)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
(S)-(+)-Citalopram Oxalate
(S)-(+)Citalopram oxalate
(s)-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
(S)-1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile oxalate
(s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5 carbonitrile
(S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Oxalate
(S)-Citalopram
(S)-Citalopram Oxalate
1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
118335-EP2275420A1
118335-EP2298764A1
118335-EP2298765A1
128196-01-0
219861-08-2
4O4S742ANY
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-, ethanedioate (1:1)
5U85DBW7LO
68P
861E082
AB0012102
AB00698374_10
AB00698374-07
AB00698374-09
AC-4508
AC-6770
AC1L3TGW
AC1L3TGZ
AJ-45648
AK138215
AK322039
AKOS016340275
AKOS017343470
AN-11923
AN-13009
AN-14764
AN-9671
AOB4715
API0010346
AX8019428
BDBM50302225
BG0433
BIDD:PXR0135
BRD-K70301876-034-02-0
BSPBio_002644
C22H23FN2O5
CAS-219861-08-2
cc-372
CCG-39559
CHEBI:36791
CHEMBL1200322
CHEMBL1508
Cipralex
Cipralex (TN)
Citalopram Oxalate
CPD000469191
CS-2053
CS-2054
CTK8E9353
D02567
D07913
D08RBC
DB01175
DR001465
DSSTox_CID_26003
DSSTox_GSID_46003
DSSTox_RID_81282
DTXSID1046003
DTXSID8048440
E0958
EBD32686
Entact
Escitalopram
Escitalopram (INN)
Escitalopram (oxalate)
Escitalopram [INN:BAN]
Escitalopram [INN]
Escitalopram for system suitability, EuropePharmacopoeia (EP) Reference Standard
Escitalopram oxalate
Escitalopram oxalate (JAN/USAN)
Escitalopram oxalate [USAN:USP]
Escitalopram oxalate [USAN]
escitalopram oxalate inn
Escitalopram oxalate, >=98% (HPLC), powder
Escitalopram oxalate, EuropePharmacopoeia (EP) Reference Standard
Escitalopram oxalate, United States Pharmacopeia (USP) Reference Standard
escitalopramum
Esertia
Esertia (TN)
FT-0650410
FT-0660873
Gaudium
GTPL7177
HE305186
HMS2051D11
HMS2089O08
HMS2231M16
HMS3370I17
HMS3393D11
HY-14258
HY-14258A
J-005570
J90016
KB-62485
KBio2_001881
KBio2_004449
KBio2_007017
KBio3_001864
KBioGR_001644
KBioSS_001881
KS-1263
KTGRHKOEFSJQNS-BDQAORGHSA-N
Lexapro (TN)
Lopac-C-7861
LS-183517
LS-183519
Lu 26-054-0
Lu-26-054-0
LU-260540
MFCD06407826
MLD-55
MLS001401408
MolPort-003-666-613
MRF-0000226
NC00194
NCGC00015267-01
NCGC00015267-02
NCGC00015267-03
NCGC00015267-06
NCGC00025160-01
NCGC00095903-01
NCGC00178555-01
NCGC00178555-02
NSC-758934
NSC758934
Pharmakon1600-01505216
R-Citalopram
RT-012495
S-(+)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate
S-(+)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile oxalate
S-(+)-5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, oxalate
S-(+)-Citalopram
S-(+)-Citalopram oxalate
S(+)-Citalopram
SAM001246668
SC-47288
SCHEMBL34948
SCHEMBL35123
Seroplex
SMR000469191
SPBio_000621
Spectrum_001401
SPECTRUM1505216
Spectrum2_000551
Spectrum3_001062
Spectrum4_001212
Spectrum5_001693
ST24046691
TL8001823
Tocris-1427
Tox21_111535
Tox21_111535_1
UNII-0DHU5B8D6V component WSEQXVZVJXJVFP-FQEVSTJZSA-N
UNII-4O4S742ANY
UNII-5U85DBW7LO
UNII-B5RDX2419X component KTGRHKOEFSJQNS-BDQAORGHSA-N
WSEQXVZVJXJVFP-FQEVSTJZSA-N
ZINC3800706

US Patents and Regulatory Information for LEXAPRO

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan Sales Llc	LEXAPRO	escitalopram oxalate	SOLUTION;ORAL	021365-001	Nov 27, 2002	AA	RX	Yes	Yes	➤ Sign Up	➤ Sign Up				➤ Sign Up
Allergan Sales Llc	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002	AB	RX	Yes	Yes	➤ Sign Up	➤ Sign Up			Y	➤ Sign Up
Allergan Sales Llc	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-002	Aug 14, 2002	AB	RX	Yes	No	➤ Sign Up	➤ Sign Up			Y	➤ Sign Up
Allergan Sales Llc	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-001	Aug 14, 2002	AB	RX	Yes	No	➤ Sign Up	➤ Sign Up			Y	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

see a sample report or, see our see our flat-rate plans

Expired US Patents for LEXAPRO

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan Sales Llc	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-002	Aug 14, 2002	➤ Sign Up	➤ Sign Up
Allergan Sales Llc	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-003	Aug 14, 2002	➤ Sign Up	➤ Sign Up
Allergan Sales Llc	LEXAPRO	escitalopram oxalate	SOLUTION;ORAL	021365-001	Nov 27, 2002	➤ Sign Up	➤ Sign Up
Allergan Sales Llc	LEXAPRO	escitalopram oxalate	TABLET;ORAL	021323-001	Aug 14, 2002	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Paragraph IV (Patent) Challenges for LEXAPRO

Drugname	Dosage	Strength	RLD	Submissiondate
➤ Subscribe	Capsules	5 mg	➤ Subscribe	2005-08-17
➤ Subscribe	Capsules	10 mg and 20 mg	➤ Subscribe	2005-03-30

see a sample report or, see our see our flat-rate plans

International Patents for LEXAPRO

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration
Malaysia	126238	➤ Sign Up
Japan	4971477	➤ Sign Up
Denmark	1522539	➤ Sign Up
Turkey	200400189	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for LEXAPRO

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB02/049	United Kingdom	➤ Sign Up	PRODUCT NAME: ESCITALOPRAM OXALATE; REGISTERED: SE 17084/85/86/87 20011207; UK PL 13761/0008 20020610; UK PC 13761/0009 20020610; UK PL 13761/0010 20020610; UK PL 13761/0011 20020610; UK PL 13761/0012 20020610; UK PL 13761/0013 20020610; UK PL 13761/00014 20020610; UK PL 13761/0015 20020610
/2002	Austria	➤ Sign Up	PRODUCT NAME: ESCITALOPRAM UND DESSEN NICHT-TOXISCHE SAEUREADDITIONSSALZE; NAT. REGISTRATION NO/DATE: 1-24549, 1-24550, 1-24551, 1-24552 20020618; FIRST REGISTRATION: SE 17084, 17085, 17086,17087 20011207
00155	Netherlands	➤ Sign Up	PRODUCT NAME: ESCITALOPRAM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER ESCITALOPRAMOXALAAT; REGISTRATION NO/DATE: RVG 30490 - RVG 30497 20040427
02C/039	Belgium	➤ Sign Up	PRODUCT NAME: ESCITALOPRAM. OXALAT. (INN) ESCITALOPRAM; NATL. REGISTRATION NO/DATE: 7004 IE10 F 3 20020729; FIRST REGISTRATION: SE 17084 20011207
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Summary for LEXAPRO

Pharmacology for LEXAPRO

Synonyms for LEXAPRO

Paragraph IV (Patent) Challenges for LEXAPRO

For more information try a trial or see the plans and pricing